Full Text View
Tabular View
No Study Results Posted
Related Studies
Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation (EMN-alloRIC)
This study is ongoing, but not recruiting participants.
Study NCT01460420   Information provided by European Myeloma Network

First Received on September 22, 2011.   Last Updated on January 22, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hematologic Malignancies
Multiple Myeloma
Additional conditions recognized in this trial
Hematologic Neoplasms
Neoplasms
Neoplasms, Plasma Cell
More general conditions related to this trial
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Neoplasms by Site
Paraproteinemias
Vascular Diseases
Interventions listed in this trial
Bz (Bortezomib)
Len (lenalidomide)
Additional drug interventions recognized in this trial
Bortezomib
Lenalidomide
Sirolimus
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Therapeutic Uses
Sponsors listed in this trial
European Myeloma Network


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services